SignaBlok presented preclinical data on efficacy of ultra high sensitivity MRI contrast agent for diagnostic imaging of atherosclerosis in a non-rodent animal model at the 2017 World Molecular Imaging Congress

SignaBlok > News > SignaBlok presented preclinical data on efficacy of ultra high sensitivity MRI contrast agent for diagnostic imaging of atherosclerosis in a non-rodent animal model at the 2017 World Molecular Imaging Congress

SignaBlok presented preclinical data on efficacy of ultra high sensitivity MRI contrast agent for diagnostic imaging of atherosclerosis in a non-rodent animal model at the 2017 World Molecular Imaging Congress

Vera

View posts by Vera
Scroll to top